Your Research, Our Expertise
Orphan Drugs


Rare disease clinical research studies pose several challenges including difficulty in diagnosis, site selection, patient enrolment and retention, and complying with regulatory requirements. One out of every five marriages in ...


More
Pediatric Trials


Biotech and pharma companies need to comply with increased regulatory requirements for paediatric trials.Yet, as per applicable regulations companies can’t adopt their adult clinical trial outcomes for paediatrics. Trial planning ...


More
Medical Device


All medical devices, regardless of their classification, require a clinical evaluation study to demonstrate the safety and performance by providing clinical evidence. Moreover, two recent regulations - Medical Device ...


More
Early Phase Trials


Clinical trials to test new treatments involve a series of steps called phases. Early phase clinical trials – phase I and phase II – are the first step in testing new medicines developed and has succesfullp passed animal testing.


More
Compassionate Use


Monitor CRO can be your partner in Turkey for helping patients and physicians for obtaining the required approvals by the Turkish Ministry of Health and obtain early access to medicines for medicines currently unavailable in their ...


More

Celebrating 21 Years!

1999 – 2020


MonitorCRO in numbers:

150+

Clinical Trials

(including registry studies)
11+

Countries

(including registry studies)
500+

Sites

(including registry studies)
50.000+

Patients

(including registry studies)


 Established in 1999, MonitorCRO is a pioneering “Contract Research Organization” in Turkey. We are a healthcare partner helping our local and global customers develop life-saving and life-improving drugs and devices with our comprehensive, high quality, and expedient research monitoring services, including data management, statistical analysis, clinical trial management, medical writing, and regulatory consulting. Our services comply with GCP guidelines and applicable local regulations. ( More.. )